The study focuses on people living with type 2 diabetes who also carry high cardiorenal risk—exactly the group targeted by modern Canadian and international guidance. Clinicians increasingly recommend initiating a GLP-1 receptor agonist and/or an SGLT2 inhibitor, independent of whether blood glucose targets have already been reached. For payers, however, the barrier has been straightforward: brand-name drug costs.

Researchers estimate that 1.3 to 2.1 million Canadians meet eligibility criteria for GLP-1RA or SGLT2i use under the Canadian Cardiovascular Society framework. At pre-generic 2025 semaglutide prices, covering all indicated patients would cost roughly $3.35 to $5.31 billion annually, typically absorbed by provincial plans or private insurers, and sometimes paid out of pocket when coverage is absent.

Using a health economic microsimulation model, the team projected lifetime costs and health outcomes, including quality-adjusted life years (QALYs), for this high-risk cohort. The simulations also accounted for the evolving burden of cardiovascular and renal comorbidities—conditions that GLP-1RAs and SGLT2 inhibitors aim to prevent or delay.

To evaluate value in a Canadian context, the authors applied the commonly used cost-effectiveness benchmark of $50,000 per QALY. They then tested how results change across a range of hypothetical generic pricing scenarios.

The modeling suggests that at a 60% price reduction, combined GLP-1RA and SGLT2i treatment could become the preferred strategy compared with using either therapy alone or other standard options. At a 70% reduction, GLP-1RA on its own appears cost-effective versus non–SGLT2i standard of care, while dual therapy remains the most economically compelling approach.

Importantly, the researchers argue that if reimbursement rules are tied to glycemic failure rather than to cardiorenal risk, payers may be missing an opportunity. Generic pricing could strengthen the rationale for aligning coverage with guideline recommendations.

Overall, the findings are positioned as actionable evidence for reimbursement and formulary decisions now that generic semaglutide availability is reducing financial uncertainty. The authors suggest the results could translate to other countries once generic GLP-1RA products reach their markets, potentially improving life quality, reducing hospitalizations, and slowing progression toward heart failure and kidney disease.

Subject of Research: Not applicable
Article Title: Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes
News Publication Date: 22-Jul-2026
Web References: https://doi.org/10.1016/j.cjca.2026.05.013
References: Canadian Journal of Cardiology (Elsevier)
Image Credits:
Keywords: generic semaglutide, cost-effectiveness, GLP-1RA, SGLT2 inhibitor, type 2 diabetes, cardiorenal risk, Canada, QALY

This alarming increase is largely attributed to the expanded use of utilization management rules, such as prior authorization requirements and step therapy protocols, designed to control escalating pharmaceutical costs. Nearly one-third of prescription denials resulted from formulary exclusions or insurer-imposed management rules, which often demand patients try alternative therapies before accessing the originally prescribed brand-name drug.

The study also highlights stark variation in rejection rates across therapeutic classes and insurance types. Incretin-based therapies for weight loss, including GLP-1 receptor agonists, faced an extreme 85% initial rejection rate, while oral anticoagulants had comparatively low denial rates near 6.7%. Marketplace exchange plans and Medicaid managed care exhibited the highest denial frequencies, with nearly half of all brand-name prescriptions initially rejected, whereas Medicare plans showed substantially lower rates.

Patients who eventually obtained their prescribed or alternative treatments experienced an average 12-day delay after rejection, and nearly half of those denied prescriptions never filled any drug in the same therapeutic category within 90 days. This raises concerns about the real-world impact of insurance barriers on timely access to necessary medications.

Researchers emphasize that these formulary-related denials occur downstream in the healthcare process, at point of pharmacy dispensing, thus not reflecting prescribers’ potential adaptation to insurance coverage constraints during initial prescribing. This disconnect may contribute to unexpected treatment delays and administrative hurdles for patients, pharmacists, and clinicians alike.

The authors suggest that integrating real-time insurance coverage information at the point of prescribing, alongside streamlined prior authorization protocols, could mitigate these barriers and reduce delays in critical treatments. However, they also caution against oversimplifying utilization management, which plays a crucial role in curbing drug spending, negotiating discounts, and promoting clinically appropriate prescribing.

While generics and biosimilars constitute 90% of prescriptions and only 12% of pharmaceutical spending, brand-name drugs continue to dominate costs, representing 88% of total spending despite accounting for just 10% of prescriptions. These dynamics underscore complex trade-offs inherent in formularies aimed at balancing cost containment with patient access.

In conclusion, this study illuminates the growing influence of insurance formulary restrictions on medication access in the United States. It calls for policy innovations that optimize utilization management without compromising patient care, ensuring that those prescribed brand-name drugs without generic equivalents can receive timely and effective treatment.

Subject of Research: Insurance denials of brand-name prescription drugs with no generic alternatives
Article Title: Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States
News Publication Date: July 9, 2024
Web References: https://jamanetwork.com/journals/jama/fullarticle/2851461
Keywords: drug costs, prescription drug spending, insurance denials, brand-name drugs, utilization management, prior authorization, formulary exclusions